Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvard Atherosclerosis Reversibility Project (HARP)
NCT00000461Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 1986
- Modality
- Device-based Delivery, Orthosteric Ligands
01
Overview
A Phase 2 trial of pravastatin, niacin, cholestyramine, gemfibrozil, omega-3 fatty acid in coronary artery disease (CAD), sponsored by National Heart, Lung, and Blood Institute. Started Dec 1986; status: completed.
02
Drugs
pravastatinniacincholestyraminegemfibrozilomega-3 fatty acid
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00000461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000461.